Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

NCT03961776 · View on ClinicalTrials.gov ↗

Study Summary

feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.

Conditions Studied

Interventions

  • DEVICE MRI-guided radiotherapy by on-board DWI sequences

Study Locations (2)

California

  • University of California Los Angeles (UCLA) — Los Angeles

Bouches Du Rhone

  • Institut Paoli Calmettes — Marseille

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2020-06-08
Est. Completion 2027-05

Sponsor

Institut Paoli-Calmettes

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03961776

The ClinicalTrials.gov registry entry for NCT03961776 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut Paoli-Calmettes, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention — of which MRI-guided radiotherapy by on-board DWI sequences is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03961776 reports 2 study locations spanning 2 distinct geographic areas — top geographies include California, Bouches Du Rhone. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03961776 about?

NCT03961776 is a clinical study titled "Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems". feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.

What is the current status of trial NCT03961776?

This trial is currently recruiting. The enrollment target is 39 participants. The study started on 2020-06-08. Estimated completion is 2027-05.

What conditions does trial NCT03961776 study?

This clinical trial studies the following conditions: Rectal Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03961776?

The interventions under investigation include: MRI-guided radiotherapy by on-board DWI sequences (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03961776?

This trial is sponsored by Institut Paoli-Calmettes, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03961776 being conducted?

This trial has 2 study locations across California, Bouches Du Rhone. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial